Navigation Links
Nektar Therapeutics Reports First Quarter 2009 Financial Results
Date:5/6/2009

(241) (40) Effect of exchange rates on cash and cash equivalents 61 10 --- --- Net decrease in cash and cash equivalents $(33,284) $(39,617) Cash and cash equivalents at beginning of period $155,584 $76,293 -------- ------- Cash and cash equivalents at end of period $122,300 $36,676 ======== =======


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
2. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
3. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
4. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
5. Nektar Therapeutics President and CEO Howard Robin to Present at 2007 BIO InvestorForum
6. Nektar Therapeutics to Present at 2007 BMO Capital Markets Focus on Healthcare Conference
7. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
8. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
9. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
10. West Concludes Agreement with Nektar
11. Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Pipette.com announces their Holiday in ... submit their #HolidayInTheLab pictures for a chance to win ... For those struggling to think of a holiday gift ... the Lab Contest provides the ideal holiday presents. The ... send pictures of their chemistree, holiday sweaters, as well ...
(Date:12/24/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ) ... Application (CTA) with the United Kingdom,s ... approval to initiate clinical trials for the continued development ... on the Company receiving CTA regulatory approval, the Company ... the safety, tolerability and dose escalation of Anatabine Citrate ...
(Date:12/22/2014)... CHAPEL HILL, N.C. , Dec. 22, 2014 ... ALNE) today announced that it has signed a ... biotechnology company that has developed and patented a ... and medical diagnostics products that enable rapid on-site ... and alcohol use/abuse and health issues in an ...
(Date:12/22/2014)... Fertility Associates of Memphis has announced ... , a network of more than 20 contributing ... have fast access to a national pool of frozen ... Fertility Associates of Memphis is the only fertility clinic ... , Dr. William Kutteh , director of Fertility ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3ALNE Announces Intention To Acquire BioTechPharma 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3
... , , , BEIJING , Feb. 8 ... in-vitro,diagnostic ("IVD") company, today announced that it will participate at the,following investor conferences in March 2010 : ... Location, ... Hotel, China Investment ...
... , NEW YORK , Feb. 8 ... relations and corporate communications for domestic and international clients, announced ... have joined as Managing Directors. , “Lisa and ... serve our clients well,” said Lynn Morgen , co-founder ...
... , , , , ... 3SBio Inc. (Nasdaq:, SSRX ) ("3SBio" or "the Company"), ... developing, manufacturing and marketing,biopharmaceutical products, today announced a collaboration ... commercialize its,Nephoxil(R) pharmaceutical product for the treatment of hyperphosphatemia ...
Cached Biology Technology:China Medical Technologies to Participate Investor Conferences in March 2010 2MBS Value Partners Hires Two New Senior Staff Members 23SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 23SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 33SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 4
(Date:12/19/2014)... Dec. 18, 2014 Research and Markets ... "Micro Market Monitor: North America Perimeter Security Systems ... http://photos.prnewswire.com/prnh/20130307/600769 The North American ... CAGR of 3.6% from 2014 to 2019. Although the ... Canada is expected to grow ...
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today ... audit to confirm its adherence to current U.S. ... enables HITLAB to conduct regulated smart device and ... for patient safety and research quality. ... quality, and delivery with innovative technology," said ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) ... Market in the APAC Region 2015-2019"  report to ... emerging in this market is advances in technology. ... to upgrade biometric solutions to the latest standard ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... infected with human immunodeficiency virus (HIV), highly active ... of Kaposi sarcoma and non-Hodgkin lymphoma, according to ... of the Journal of the National Cancer Institute. ... (AIDS) have reported increased risks of several cancers, ...
... short pulses is a promising, non-invasive procedure for ... healthy tissue, according to a study in the ... focused ultrasound (HIFU) is more powerful than standard ... continuous exposures that raise the temperature inside cancerous ...
... the NIH new policy from yesterday : ... rule on Enhanced Public Access to NIH Research Information ... opportunity to take advantage of available technology and existing ... not-for-profit medical and scientific publishers. The final rule ignores ...
Cached Biology News:Antiretroviral therapy may prevent excess risk of some cancers in people with HIV 2Pulsating ultrasound enhances gene therapy for tumors 2Not-for-profit publishers call NIH public access rule a missed opportunity 2Not-for-profit publishers call NIH public access rule a missed opportunity 3
Request Info...
... The Zero Blunt ... for Sequencing is designed ... sequencing of blunt-end PCR ... provides 5-minute TOPO Cloning ...
... 1 kit. Convenient way to ... Conjugations are carried out under mild conditions ... Dyes are packaged in premeasured amounts and ... Category: Blotting & Labeling & Detection, Protein ...
...
Biology Products: